Infant formulas containing non-digestible oligosaccharides (NDO) similar to the composition in breast milk or a combination of lactic acid bacteria (LAB) and NDO have been shown to harbor preventive effects towards immune-regulatory disorders. The aim of this study was to investigate the immune-modulatory potential of non-digestible short chain galacto-and long chain fructo-oligosaccharides (scGOS/lcFOS) mimicking the natural distribution of oligosaccharides in human breast milk in presence or absence of certain LAB strains in human monocyte derived dendritic cells (MoDC). Immature human MoDC prepared from peripheral blood of healthy non-atopic volunteers were screened in vitro after stimulation with specific scGOS/lcFOS in presence or absence of LAB. IL-10 and IL-12p70 release was analyzed after 24 hours in cell-free supernatants by enzyme-linked immunosorbent assay (ELISA). A luminex-based assay was conducted to assess further cytokine and chemokine release by MoDC. To investigate the resulting T cell response, stimulated MoDC were coincubated with naïve T cells in allogeneic stimulation assays and intracellular Foxp3 expression, as well as immune-suppressive capacity was determined. Oligosaccharides did not induce relevant amounts of IL-12p70 production, but did promote IL-10 release by MoDC. Furthermore, scGOS/lcFOS mixtures exerted a significant enhancing effect on LAB induced IL-10 secretion by MoDC while no increase in IL-12p70 production was observed. Blocking toll like receptor (TLR)4 abrogated the increase in IL-10 in both the direct stimulation and the LAB stimulation of MoDC, suggesting that scGOS/lcFOS act via TLR4. Finally, scGOS/ lcFOS-treated MoDC were shown to upregulate the number of functional suppressive Foxp3 positive T cells following allogeneic stimulation. Our results indicate anti-inflammatory and direct, microbiota independent, immune-modulatory properties of scGOS/lcFOS mixtures on human MoDC suggesting a possible induction of regulatory T cells (Tregs). The
Introduction
Over the past decades predominantly western countries are facing an increasing occurrence of chronic inflammatory diseases associated with loss of tolerance such as allergies or inflammatory bowel disease. Accumulated evidence suggests a link between these immune-regulatory disorders and an imbalance in the intestinal microbiota also referred to as dysbiosis [1] [2] [3] . An adequate constitution of the intestinal microbiota and gut colonization in early stages of life is crucial for maintaining health as adult [4] . It has been shown that the infant's immune system matures by exposure to the intestinal microbiota initiated by microbial colonization of the gut through exposure to bacteria during birth and early life [5, 6] . Evidence exists that breastfeeding decreases the incidence of infections [7] and can be protective regarding allergic diseases [8, 9] . Human milk plays an important role in the establishment of the microbiota and the maturation of the child's immune system [10] through its unique composition involving antimicrobial properties, transfer of immunological and tolerogenic stimuli and its high content of nondigestible human milk oligosaccharides (HMO) [11, 12] . Infant formula supplemented with a specific manufactured 9:1 mixture of short chain galacto-oligosaccharides and long chain fructo-oligosaccharides (scGOS/lcFOS), resembling the composition of HMO is associated with a reduced cumulative incidence of atopic dermatitis during the first six month of life. In a follow-up study, a protective effect on the incidence of some allergic manifestations could be observed after five years [13, 14] . Moreover, a decreased occurrence of allergic manifestations at the age of two and a reduced number of infectious episodes beyond the intervention period have been reported in infants that received formula containing scGOS/lcFOS [15] . Additionally, other studies showed a beneficial effect on mucosal immunity showing higher concentrations of fecal secretory immunoglobulin (Ig)A [16, 17] , reduced levels of immunoglobulin free light chain, and a beneficial immunoglobulin profile in infants at high risk for allergy [18, 19] . Overall, these data suggest that infant formula supplemented with this specific mixture of scGOS/lcFOS has immune-regulatory properties but much remains unknown about their mechanism of action. Besides the known prebiotic effects of NDO on modulating the composition of the intestinal microbiota [20, 21] possible direct systemic effects of NDO on epithelial and immune cells are currently under investigation [22] . Naarding et al. showed that HMO have the capacity to bind to the C-type lectin receptor dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) on dendritic cells (DC) [23] and CapitanCanadas et al. recently described a non-prebiotic effect of oligosaccharides on monocytes via activation of the pattern recognition receptor (PRR) Toll like receptor 4 (TLR4) in rats [24] . In a follow-up study, a TLR4-mediated direct effect of NDO on human intestinal epithelial cell lines could be demonstrated [25] .
In this study, we analyzed the direct immune-modulatory effects of scGOS/lcFOS on MoDC. We show that MoDC stimulation with scGOS/lcFOS increases IL-10 release in the absence of IL-12 secretion. Furthermore, scGOS/lcFOS-treated MoDC were found to increase the number of Foxp3 + T cells. Overall scGOS/lcFOS might contribute to intestinal homeostasis via the induction of the anti-inflammatory cytokine IL-10 and the induction of Tregs.
Methods

Subjects and Ethic Statement
For this study peripheral blood of healthy, non-atopic donors was used. Volunteers were screened for total serum IgE levels and for specific IgE against common allergens as described before [26] and non-atopic individuals were defined by total IgE lower 100 kU. The ethical committee of Technische Universität München approved the study and all volunteers enrolled in the study had given their written informed consent.
Bacteria Preparation
The Bifidobacterium breve strain NutRes200 as well as the Lactobacillus rhamnosus strain NutRes1 were used. L.rhamnosus was available as 0.5 ml cultures of 5.9x10 9 cell counts stored at -80°C. Lyophilized B.breve was diluted in D-PBS (Gibco/Invitrogen) and a 25x10 9 cfu/ml stock solution was prepared and stored at -80°C. To prepare bacterial strains for stimulation experiments, stocks were thawed, diluted appropriately in D-PBS (Gibco/Invitrogen) and concentrations of 1x10
cfu/ml were generated by serial dilution in cell culture medium.
Generation of Monocyte Derived Dendritic Cells
For the generation of monocyte derived dendritic cells (MoDC) PBMC were isolated from peripheral blood of healthy volunteers by density gradient centrifugation (Lymphoprep, AxisShield 
Stimulation of MoDC with scGOS/lcFOS and LAB
Immature MoDC were seeded into 96-well flat bottom plates (Nunc) at a density of 1x10 5 cells/ml in complete DC medium and treated with the bacterial strains at concentrations of 1x10 5 -1x10 7 cfu/ml. Bacterial stimulation was performed either in the absence or presence of 5mg/ml scGOS/lcFOS mixture (9:1; scGOS; Friesland Campina, lcFOS; Orafti). To block TLR4 activity, a TLR4 antagonist (5 μg/ml, LPS-RS Ultrapure, InvivoGen) was used. LPS (100 ng/ml, Sigma) served as positive control for MoDC stimulation indicating functional MoDC stimulation. Untreated MoDC were used as negative control. After 24 hours incubation at 37°C and 5% CO 2 , cytokines IL-10 (BD Biosciences) and IL-12p70 (eBioscience) were analyzed in cellculture supernatants by ELISA according to the manufacturer's protocol. Furthermore, a broader selection of MoDC released mediators were analyzed by a luminex-based assay conducted by the Multiplex Core Facility Laboratory for Translational Immunology, Department of Pediatric Immunology, University Medical Centre Utrecht. Expression of maturation markers CD80 (FITC-conjugated anti-human, BD), CD83 (PE-conjugated anti-human, eBioscience), CD86 (APC-conjugated anti-human, BD), CD40 (FITC-conjugated anti-human, eBioscience), HLA-DR (APC-conjugated anti-human, eBioscience) and viability were measured by flow cytometry after stimulation of MoDC.
Allogeneic Stimulation Assay of Naïve T cells
The capacity of oligosaccharides-matured MoDC to instruct the polarization of T lymphocytes was examined performing allogeneic stimulation assays (ASA). After 24 hours scGOS/lcFOSstimulated MoDC were washed and co-incubated with naïve CD4 + CD45RA + T cells at a DC:T cell ratio of 1:10 in T cell medium containing RPMI supplemented with 1% L-glutamine, 1.12% nonessential amino acids, 1.12% sodium pyruvate, 1% pen-strep (all from Gibco), 1% 5 mM mercaptoethanol and human serum (5%, Lonza) for 7 days. Allogeneic CD4 + CD45RA + T cells were isolated from PBMC of non-atopic donors using the CD4 + CD45RA + naïve T Cell
Isolation Kit II (Miltenyi Biotech). A positive control for Treg polarization was generated by priming naïve T cells with 5 ng/ml rhTGF-β (Promokine), 200 U/ml rhIL-2 (Novartis), 5 μg/ ml anti-IL-12 and 1 μg/ml aIFN-γ (both eBioscience) and co-culturing them with MoDC that have been incubated with medium only. 20 U/ml rhIL-2 was added to the cells on the third day of the ASA. After 7 days of co-culture cells were restimulated for 5 hours with phorbol 12-myristate 13-acetate/ionomycin (both Sigma Aldrich) in the presence of monensin (eBioscience) and brefeldin A (BD Biosciences). Dead cells were excluded using the LIVE/ DEAD Fixable Aqua dead cell stain kit (Life Technologies) according to the manufacturer's instructions, followed by surface staining of CD4 (APC-Cy7-conjugated anti-human, BD Biosciences). Cells were then fixed, permeabilized and stained for intracellular Foxp3 (APCconjugated anti-human, eBioscience) using a Foxp3 staining kit (eBioscience) and analyzed by flow cytometry (FACSFortessa System, BD FACSDiva 7.0). The gating strategy of alive, CD4 + ,
Suppression Assay
To determine the functionality of potential regulatory effector T cells induced in the ASA, these cells were harvested on day seven of the ASA and co-incubated with allogeneic freshly isolated responder T cells (CD4 + T cell isolation Kit II, Miltenyi) at a ratio of 1:1 for five days in 96-well plates (BD) coated with anti-CD3 (1 μg/ml, BD). Soluble anti-CD28 (1 μg/ml, BD) and rhIL-2 (100 U/ml) were added. Responder T cells were stained with Cell Trace Violet Cell Proliferation Kit (Life Technologies) according to the manufacturers' instructions at a final concentration of 6 μM and violet-positive cells were acquired on a FACS Fortessa (BD). The mix of ASA cells and violet stained responder CD4+ T cells was then stained (after five days of coincubation) with CD4 APC-Cy7. Suppressive capacity was determined by setting gates on proliferated and non-proliferated cells and analyzing the ratio of these cell populations. The gating strategy of dividing/non-dividing CD4 + T cells is shown in S6 Fig.
Statistical Analysis
Data are presented as mean ± SEM and statistically analyzed using the Mann-Whitney-Test or unpaired student's t test, a p 0.05 was considered as statistically significant. Statistical analysis was conducted using GraphPad Prism software (version 6.0).
Results
scGOS/lcFOS Induce IL-10 Secretion of MoDC in the Absence of IL12p70
To investigate whether scGOS/lcFOS can induce cytokine release by MoDC, immature human MoDC were stimulated with scGOS/lcFOS (5 mg/ml). The incubation of MoDC with oligosaccharides induced the release of IL-10 ( Fig 1A) , while no IL-12p70 release could be detected ( Fig  1B) . LPS-stimulated MoDC released both IL-10 and IL-12p70 (Fig 1A and 1B ).
MoDC were phenotypically analyzed after incubation with either medium, LPS or oligosaccharides. Compared to medium, LPS induces maturation as measured by increased mean fluorescence intensities (MFI) specific for maturation markers CD80, CD83 and CD86. In contrast treatment with oligosaccharides only slightly upregulated maturation markers (S2 
scGOS/lcFOS Dose-dependently Activate TLR4
NDO were previously shown to stimulate TLR4 [25] . To investigate the potential involvement of TLR4 in the MoDC cytokine release following scGOS/lcFOS stimulation, we conducted a dose-response experiment in the presence and absence of a TLR4 antagonist. Stimulating MoDC with scGOS/lcFOS in the presence of the TLR4 antagonist completely abrogated MoDC IL-10 release (Fig 2, controls see S3 Fig) . The observation that, in contrast to LPS, scGOS/lcFOS stimulated MoDC released IL-10 in the absence of IL-12 led us to consider whether other soluble mediators were also differentially affected. Upon comparing the LPS-with the scGOS/lcFOS-induced MoDC profile of mediator release several differences could be observed depending on the secreted mediator (Fig 3) .
scGOS/lcFOS Enhance LAB-induced IL-10 Release
To examine how the presence of scGOS/lcFOS would affect LAB-induced MoDC cytokine release, MoDC were stimulated with either B.breve or L.rhamnosus in the absence or presence of scGOS/lcFOS. In contrast to L.rhamnosus, B.breve induced IL-10 release in the absence of IL-12p70 (S4 Fig). Presence of scGOS/lcFOS significantly enhanced IL-10 release for both strains while IL-12p70 release was not affected (Fig 4) .
To investigate this differential effect on cytokine release in more detail, a larger selection of MoDC-derived soluble mediators was analyzed. scGOS/lcFOS was found to enhance mediator release depending both on the analyte measured and the bacterial strain used suggesting straindependent effects (S5 Fig). To investigate the potential contribution of TLR4 activity to the observed effect, MoDC were stimulated in the presence of a LPS antagonist. scGOS/lcFOS dose-dependently increased B.breve-induced MoDC IL-10 release. Blocking of TLR4-activity abrogated this enhanced effect (Fig 5) . Fig 6B) , scGOS/lcFOSstimulated DC induced an upward shift in Foxp3 expressing T cells (Fig 6C) . However, this increase did not reach significance (Fig 6D) .
These induced CD4 + Foxp3 + T cells differentiated by scGOS/lcFOS-stimulated MoDC showed in suppression assays an increased capacity to inhibit the proliferation of CD4 + responder cells (Fig 7A and 7E ) compared to T cells induced by medium-/LPS-treated MoDC and Treg control (Fig 7B-7D T cells are characterized by a low suppressive functionality index comparable to Treg control which indicates a high capacity to inhibit the proliferation of CD4 + responder cells.
Discussion
It has been reported in animal trials and human clinical studies that NDO like scGOS/lcFOS supplemented to infant formula can contribute to a decreased susceptibility to atopy and allergy [16, [28] [29] [30] . However, the exact mechanisms are still unclear but might involve the direct effects of NDO on host-cells [31] . The specific mixture of scGOS/lcFOS, as used in this study, was previously found to modulate cytokine release from CD3/CD28 stimulated PBMC both directly and through effects on epithelial cells in 2D co-cultures [32] , which suggest that scGOS/lcFOS might stimulate (immune) cells directly. In this study, we evaluated whether scGOS/lcFOS exert direct immune-modulatory effects on human MoDC. For the first time we show direct, immune-modulatory effects of this unique combination of oligosaccharides on human MoDC and the ensuing induced T cell response. We have shown that DC treated with scGOS/lcFOS released IL-10 in the absence of IL-12p70 and that this effect is mediated via activation of TLR4. In contrast, TLR4 activation through LPS stimulation of MoDC released both IL-10 and IL-12, which would argue against a potential bacterial product contamination of the scGOS/lcFOS preparation. In line with this, upon measuring the endotoxin content of the scGOS/lcFOS preparation using a LAL-assay, endotoxin content was measured to be very low (<3 ng/ml). Moreover, upon analysis of additional soluble mediators (chemokines as well as cytokines) the profile of scGOS/lcFOS induced release was markedly different from LPS, suggesting that other PRR may play a role. Several studies describe an immune modulation by different NDO on cellular level via the interaction with specific sugar receptors including DC-SIGN, TLRs or C type lectin receptors [24, 25, [33] [34] [35] . Further studies in our experimental setting are necessary to investigate the role of other types of receptors involved in scGOS/lcFOS-mediated, direct mechanisms on human MoDC. Synbiotics, which are a specific mixture of probiotic bacteria and prebiotic NDO, can be ingredients of infant milk formulas [36] . Here the prebiotics are thought to act as substrates for the probiotic bacteria thereby assisting in their probiotic function. Strains from Bifidobacteria and Lactobacilli are often considered as potential probiotic bacteria [37] . Here we evaluated the contribution of the prebiotic mixture scGOS/lcFOS on the probiotic bacteria-induced MoDC cytokine profile. MoDC strain-dependently released IL-10 and IL-12. This is in accordance with previous data showing that different bacterial strains have different, straindependent effects on cytokine release of human immune cells potentially through the differential use of PRR [38] [39] [40] [41] . In line with the data observed on the direct effects of scGOS/lcFOS on MoDC, the scGOS/lcFOS mixtures dose-dependently enhanced B.breve and L.rhamnosus induced IL-10 release while IL-12 release was unaffected. Again, this effect could be blocked using a LPS antagonist indicating a role for TLR4 in the observed effect. DC production of IL-10 in the absence of IL-12p70 could contribute to the development of regulatory T cells [27, [42] [43] [44] . Additionally, treatment with oligosaccharides only slightly upregulated maturation [27, 45] . Experiments of this study show that treatment of MoDC with scGOS/lcFOS led to an increase in Foxp3 + T cells, which is associated with an increase in Treg [46, 47] . Treg induction by scGOS/lcFOS shown in this study is in accordance with previous studies where a diet containing scGOS/lcFOS increased vaccination responses in mice but also decreased allergic symptoms in a mouse model of food-allergy [48, 49] . According to van der Aa et al. a combination of B.breve and scGOS/lcFOS induces Treg cell development through modulation of DC function, preventing asthma-like symptoms in infants with atopic dermatitis [50] . An intervention study in a mouse model for orally induced cow's milk allergy revealed a reduced acute allergic skin response and anaphylactic scores after dietary intervention with scGOS/lcFOS in combination with B.breve. Also enhanced whey-specific Th1 type serum IgG2a, fecal IgA and reduced mast cell degranulation was found in this study [51] . The authors suggested a possible involvement of whey-specific CD25 + regulatory T cells in induction of tolerance by NDO and confirmed a role for regulatory T cells in suppressing casein allergy by NDO [49, 52] . An important role of regulatory T cells as well as anti-inflammatory cytokine profiles in the prevention of allergies and related disorders has been affirmed by several studies [53] [54] [55] . Finally, the results of our study provide support that the clinical efficacy of scGOS/lcFOS displaying similar functionality as HMO supplemented to infant formula may also relate in part to direct interaction with immune cells. Our data provides evidence for a (TIF)
